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Patients in intensive care units (ICUs) are treated with many in-terventions (most notably endotracheal intubation and invasive mechanical ventilation) that are observed or perceived to be distressing. Pain is the most 
common memory patients have of their ICU stay.1 Agitation can precipitate acciden-
tal removal of endotracheal tubes or of intravascular catheters used for monitoring 
or administration of life-sustaining medications. Consequently, sedatives and analge-
sics are among the most commonly administered drugs in ICUs.
Early intensive care practice evolved from intraoperative anesthetic care at a 
time when mechanical ventilation was delivered by rudimentary machines that 
were not capable of synchronizing with patients’ respiratory efforts. As a result, 
deep sedation was commonly used until a patient was able to breathe without as-
sistance. Developments over the past 30 years, including microprocessor-controlled 
ventilators that synchronize with patients’ own respiratory efforts and new, 
shorter-acting sedative and analgesic medications, have dramatically changed this 
approach. Equally important has been the recognition that pain, oversedation, and 
delirium are issues that if undetected and untreated are distressing to patients and 
associated with increased morbidity and mortality.
Just as the concept of the “triad of anesthesia” underscores the pharmacody-
namic interactions among hypnotics, analgesics, and muscle relaxants and the 
recognition that the simultaneous administration of agents of each class permits 
the use of lower doses of drugs of all classes, the concept of the “ICU triad” rec-
ognizes that pain, agitation, and delirium — and therefore approaches to their 
management — are inextricably linked (Fig. 1). According to the principle that it 
is better to treat disease than to mask it, sedatives should be used only when pain 
and delirium have been addressed with the use of specific pharmacologic and 
nonpharmacologic strategies.
Pa in,  A na l gesi a ,  a nd Sedation in the ICU
Prospective studies confirm that the majority of patients who are treated in ICUs 
have pain,1 which makes the assessment of pain and provision of adequate analge-
sia essential components of ICU care. The short-term consequences of untreated 
pain include higher energy expenditure and immunomodulation.2,3 Longer-term, 
untreated pain increases the risk of post-traumatic stress disorder.4 Assessing 
whether a patient in the ICU is in pain may be difficult. The reference standard for 
the assessment of pain is self-reporting by the patient, but patients in the ICU may 
not be sufficiently interactive to give valid responses. Physiological indicators such 
as hypertension and tachycardia correlate poorly with more intuitively valid mea-
sures of pain,5 but pain scales such as the Behavioral Pain Scale6 and the Critical 
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Care Pain Observation Tool7 provide structured 
and repeatable assessments and are currently the 
best available methods for assessing pain.
A minority of ICU patients have an indication 
for continuous deep sedation, for reasons such 
as the treatment of intracranial hypertension, 
severe respiratory failure, refractory status epi-
lepticus, and prevention of awareness in patients 
treated with neuromuscular blocking agents. This 
review will focus on the remaining overwhelm-
ing majority of patients undergoing mechanical 
ventilation for whom the use of sedatives and 
analgesics should be minimized, with the goal 
that they be calm, lucid, pain-free, interactive, 
and cooperative with their care.
Evidence from randomized, controlled trials 
consistently supports the use of the minimum 
possible level of sedation. In a landmark trial 
that compared routine daily interruption of seda-
tive infusions with discretionary interruption by 
treating clinicians, patients whose sedation was 
routinely interrupted received less sedation over-
all and spent fewer days undergoing mechanical 
ventilation and fewer days in the ICU.8 Although 
the trial was too small to assess differences in 
mortality or discharge destination, the observed 
reductions in the duration of mechanical ventila-
tion and length of stay in the ICU were associated 
with a nonsignificant reduction in mortality and a 
nonsignificant increase in the proportion of pa-
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Figure 1. Causes and Interactions of Pain, Agitation, and Delirium.
Drugs and other treatments for pain, agitation, and delirium form an “ICU triad” cognitive management analogous 
to the “triad of anesthesia,” which highlights interactions among hypnotics, analgesics, and muscle relaxants to en­
courage balanced anesthesia. The “ICU triad” concept highlights that changing one element is unlikely to be as ef­
fective as a coordinated approach.
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tients who were discharged to their own homes.8 
A subsequent larger multicenter trial combined 
the daily interruption of sedation with daily spon-
taneous breathing trials.9 Daily interruption of 
sedation was associated with reduced adminis-
tration of a benzodiazepine sedative, reduced 
duration of mechanical ventilation, reduced length 
of stay in the ICU, and significantly increased 
survival. In contrast, when daily interruption of 
sedation was added to a protocol for sedation 
practice that already sought to minimize the 
level of sedation, the total sedative dose was in-
creased and there was no clinical benefit.10
These conflicting results are open to a number 
of interpretations, including that daily interrup-
tion is beneficial only when it results in a reduc-
tion in the total dose of sedative administered. 
The conflicting findings also highlight that the 
results of daily interruption of sedation may be 
context-specific and will depend on the popula-
tion being studied, protocol adherence, and 
management of the control group. A random-
ized, controlled trial in which all patients under-
going mechanical ventilation received morphine 
for the treatment of pain in an “analgesia first” 
approach compared a protocol of no sedation 
with the routine use of sedation with daily inter-
ruption.11 Patients who were assigned to the 
protocol of no sedation had shorter stays in the 
ICU and the hospital and more days without 
mechanical ventilation.
The consistent message from all these sedation-
interruption trials is that minimizing sedation 
among patients in the ICU provides clinical 
benefit. Further support comes from a prospec-
tive, multicenter, longitudinal cohort study show-
ing that the depth of sedation was independently 
associated with the duration of mechanical 
ventilation, in-hospital mortality, and rates of 
death within 180 days.12 In a randomized, con-
trolled trial, the use of lighter sedation resulted 
in more ventilator-free and ICU-free days.13 In 
comparison with deep sedation, the use of lighter 
sedation did not increase the rate of short-term 
adverse events, and long-term psychiatric out-
comes were either unaffected or improved.13-16
Choice of Sedati v e Agen t
Despite at least 90 trials comparing sedative reg-
imens,17 in general, no sedative drug is clearly 
superior to all others. Sedatives that are com-
monly used in the ICU are the benzodiazepines 
midazolam and lorazepam (and to a lesser ex-
tent, diazepam), the short-acting intravenous an-
esthetic agent propofol, and dexmedetomidine.12 
Remifentanil, an opioid, is also used as a sole 
agent because of its sedative effects. Benzodiaz-
epines act through γ-aminobutyric acid type A 
(GABAa) receptors, as in part does propofol, 
whereas dexmedetomidine is an α2-adrenoceptor 
agonist, and remifentanil is a μ-opioid receptor 
agonist (Table 1). Marked differences in prescrib-
ing patterns among countries suggest that the 
choice of agent is determined more by tradition 
and familiarity than by evidence-based practice.
If minimizing the depth and duration of se-
dation is accepted as a desirable goal, then the 
use of a short-acting agent with an effect that 
can be rapidly adjusted such as propofol or remi-
fentanil should offer advantages over longer-
acting agents or agents with active metabolites. 
As compared with benzodiazepines, propofol has 
not been shown to reduce mortality but may 
result in a reduction in the length of stay in the 
ICU.18 Dexmedetomidine may also have advan-
tages over benzodiazepines, since it produces 
analgesia, causes less respiratory depression, and 
seemingly provides a qualitatively different type 
of sedation in which patients are more interac-
tive and so potentially better able to communi-
cate their needs.19 As compared with lorazepam 
and midazolam, dexmedetomidine resulted in less 
delirium and a shorter duration of mechanical 
ventilation but not reduced stays in the ICU or 
hospital.19-21 When two short-acting and titrat-
able drugs such as propofol and dexmedetomi-
dine were compared, there was no significant 
difference in the time spent at the target seda-
tion level and no difference in either the duration 
of mechanical ventilation or ICU stay.19
Remifentanil has a half-life of 3 to 4 minutes 
that is independent of the infusion duration or 
organ function. It has been investigated as a 
sedative agent in ICUs predominantly among sur-
gical patients. It has been compared with mid-
azolam alone, midazolam with fentanyl, fentanyl 
alone, and morphine.22-25 Although remifentanil 
has been associated with a reduced duration of 
mechanical ventilation and ICU stay in these 
small trials, it has not yet been evaluated in a 
large, heterogeneous population of critically ill 
patients and is currently not a common choice in 
most ICUs.
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Pr e v en tion a nd Tr e atmen t  
of Delir ium
The Diagnostic and Statistical Manual of Mental Disor-
ders, 4th edition (DSM-IV),26 lists four domains of 
delirium: disturbance of consciousness, change 
in cognition, development over a short period, 
and fluctuation. Delirium is defined by the Na-
tional Institutes of Health as “sudden severe con-
fusion and rapid changes in brain function that 
occur with physical or mental illness.” The most 
common feature of delirium, thought by many to 
be its cardinal sign, is inattention. Delirium is a 
nonspecific but generally reversible manifesta-
tion of acute illness that appears to have many 
causes, including recovery from a sedated or 
oversedated state.
The pathophysiology of delirium that is associ-
ated with critical illness remains largely unchar-
acterized and may vary depending on the cause. 
The increased risk associated with the use of 
GABAa agonists and anticholinergic drugs led to 
the suggestion that the GABAergic and choliner-
gic neurotransmitter systems play a contributory 
role. In particular, central cholinergic deficiency 
may be a final common pathway. Alternative 
hypotheses include excess dopaminergic activity 
and direct neurotoxic effects of inflammatory 
cytokines. Currently, these hypotheses are un-
proven, making pharmacologic management 
strategies largely empirical.
Studies using magnetic resonance imaging 
have shown a positive association between the 
duration of delirium in the ICU and both cere-
bral atrophy and cerebral white-matter disrup-
tion.27,28 These preliminary investigations indi-
cate either that delirium in the ICU gives rise to 
alterations in brain structure or that the presence 
of such cerebral atrophy and white-matter disrup-
tion renders patients more susceptible to delirium.
Regardless of the cause and the underlying 
pathophysiology, delirium is now recognized as a 
frequent and serious event in critically ill patients. 
There is no diagnostic blood, electrophysiologi-
cal, or imaging test for delirium, which there-
fore remains a clinical diagnosis. Estimates for 
the incidence of delirium in the ICU range from 
16%29 to 89%,30 with the reported incidence af-
fected both by the characteristics of the popula-
tion being studied and by the diagnostic criteria 
used. Risk factors that have been identified in-
clude an advanced age and the presence of more 
than one condition associated with coma, fol-
lowed by treatment with sedative medications, a 
neurologic diagnosis, and increased severity of 
illness.31 A diagnosis of delirium is associated 
with increased mortality (estimated as a 10% 
increase in the relative risk of death for each day 
of delirium32) and decreased long-term cognitive 
function.33
There are two distinct forms of delirium, 
hypoactive and agitated (or hyperactive). When 
individual patients intermittently have both forms, 
it is termed mixed delirium. The hypoactive 
form is characterized by inattention, disordered 
thinking, and a decreased level of consciousness 
without agitation. Pure agitated delirium affects 
less than 2% of patients with delirium in the ICU.34 
Patients with hypoactive delirium are the least 
likely to survive, but those who do survive may 
have better long-term function than those with 
agitated or mixed delirium.33 Separating the ef-
fects of delirium status from those of illness 
severity with respect to the risk of death is dif-
ficult, since patients with more serious illnesses 
are at increased risk for both delirium and death. 
Association studies typically adjust for illness 
severity on admission to the ICU rather than at 
the time that delirium is diagnosed. Although the 
association between delirium and a worse out-
come is clear, a causal relationship has not been 
established. Currently, the evidence that specific 
treatment of delirium may improve outcomes is 
tenuous.
A ssessmen t a nd Moni t or ing  
of Sedation a nd Delir ium
Although ICU practice is characterized by close 
monitoring of carefully administered care, sur-
veys that have been conducted in various coun-
tries have shown that the depth of sedation fre-
quently goes unmonitored.35 This finding is 
surprising and unacceptable, since evidence sug-
gests that the routine monitoring of sedation 
may improve patients’ outcomes.36
Sedation Scales
Of the sedation scales described, the Riker 
 Sedation–Agitation Scale37 and the Richmond 
Agitation–Sedation Scale38 are the most com-
monly reported, but in head-to-head comparison, 
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neither is demonstrably superior39 (Table 2). For 
the majority of patients undergoing mechanical 
ventilation in an ICU, an appropriate target is a 
score of 3 to 4 on the Riker Sedation–Agitation 
Scale (which ranges from 1 to 7, with scores of 
<4 indicating deeper sedation, a score of 4 indi-
cating an appearance of calm and cooperative-
ness, and scores of ≥5 indicating increasing agi-
tation) or a score of −2 to 0 on the Richmond 
Agitation–Sedation Scale (which ranges from −5 
to +4, with more negative scores indicating deep-
er sedation and more positive scores indicating 
increasing agitation, and with 0 representing the 
appearance of calm and normal alertness).
Identifying Delirium
In routine practice, ICU staff members typically 
do not diagnose delirium in almost three quar-
ters of their patients who have the condition, 
whereas active screening by research nurses 
identified delirium in up to 64% of patients who 
were considered to be delirious by a psychiatrist, 
a geriatrician, or a neurologist.40 Scales with re-
spect to delirium in the ICU apply the four DSM-IV 
domains defining delirium in general medical 
and psychiatric patients to those in the ICU whose 
severity of illness can rapidly fluctuate, who re-
ceive multiple analgesics and sedatives, and who 
are unable to speak owing to endotracheal intuba-
tion. Two scales are in common use, the Confu-
sion Assessment Method for the ICU (CAM-ICU)41 
and the Intensive Care Delirium Screening Check-
list (ICDSC)29 (Table 3). The CAM-ICU reports a 
dichotomous assessment at a single time point, 
whereas the ICDSC lists signs that can be ob-
served over a period of time. Although such 
Table 2. Sedation Scales for Patients in the ICU.
Scale and Scoring Method Description
Riker Sedation–Agitation Scale (SAS)*
Dangerous agitation (score of 7) Pulling at endotracheal tube, trying to remove catheters, climbing over bed rail, 
striking at staff, thrashing from side to side
Very agitated (score of 6) Requiring restraint and frequent verbal reminding of limits, biting endotracheal tube
Agitated (score of 5) Anxious or physically agitated, calming at verbal instruction
Calm and cooperative (score of 4) Calm, easily rousable, follows commands
Sedated (score of 3) Difficult to arouse but awakens to verbal stimuli or gentle shaking; follows 
simple commands but drifts off again
Very sedated (score of 2) Arouses to physical stimuli but does not communicate or follow commands, 
may move spontaneously
Cannot be aroused (score of 1) Minimal or no response to noxious stimuli, does not communicate or follow 
commands
Richmond Agitation–Sedation Scale (RASS)†
Combative (score of 4) Overtly combative, violent, immediate danger to staff
Very agitated (score of 3) Pulls or removes tubes or catheters; aggressive
Agitated (score of 2) Frequent nonpurposeful movement, fights ventilator
Restless (score of 1) Anxious but movements not aggressive or vigorous
Alert and calm (score of 0) Alert and calm
Drowsy (score of −1) Not fully alert but has sustained awakening (eye opening or eye contact) to 
voice (≥10 sec)
Light sedation (score of −2) Briefly awakens with eye contact to voice (<10 sec)
Moderate sedation (score of −3) Movement or eye opening to voice but no eye contact
Deep sedation (score of −4) No response to voice but movement or eye opening to physical stimulation
Cannot be aroused (score of −5) No response to voice or physical stimulation
* Data are from Riker et al.37
† Data are from Sessler et al.38
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scales are essential in objectively diagnosing de-
lirium for research purposes, it is not clear that 
the use of these scales is more sensitive than un-
structured assessments made by trained bedside 
nurses who are prompted to look for delirium. 
Some studies have shown a high sensitivity when 
such assessments are performed by bedside 
nurses,42 whereas other studies have shown con-
flicting results.43 Used alone (without an accom-
panying sedation scale), none of the published 
scales distinguish hyperactive from hypoactive 
delirium, and none of the published scales quan-
tify the relative importance of individual elements 
of the scales despite recognition that specific 
treatments may shorten the duration of some ele-
ments and prolong the duration of others. All the 
scales dichotomize delirium as being either pres-
ent or absent, although it would seem to be in-
tuitive that delirium has different degrees of se-
verity. The CAM-ICU and ICDSC are currently the 
two accepted methods for identifying a condition 
that otherwise frequently goes undiagnosed.44
Pr e v en tion a nd Tr e atmen t 
of Delir ium
Prevention
There is some evidence that delirium can be pre-
vented. Outside the ICU, repeated reorientation, 
noise reduction, cognitive stimulation, vision and 
hearing aids, adequate hydration, and early mo-
bilization can reduce the incidence of delirium in 
hospitalized patients.45 Haloperidol prophylaxis 
in patients undergoing hip surgery reduced the 
severity and duration of delirium.46 Among pa-
tients in the ICU, the duration of delirium was 
cut in half with early mobilization during inter-
ruptions in sedation.47
Pharmacologic studies of delirium prevention 
include trials comparing one sedative–analgesic 
regimen with another and studies of antipsychotic 
drugs administered with the specific intent of 
preventing delirium. Four placebo-controlled 
trials have evaluated pharmacologic prophylaxis 
of delirium; low-dose haloperidol48 and low-dose 
risperidone49 both reduced the incidence of de-
lirium, as did a single low dose of ketamine 
during the induction of anesthesia.50 However, 
these trials were conducted among patients un-
dergoing elective surgical procedures, and it is 
not clear whether their results can be extrapo-
lated to the general ICU population. In contrast, 
the cholinesterase inhibitor rivastigmine was 
ineffective in preventing delirium.51
Sedation with dexmedetomidine rather than 
benzodiazepines appears to reduce the incidence 
of delirium in the ICU. In a multicenter, ran-
domized trial predominantly involving medical 
patients in the ICU, the administration of dex-
medetomidine or midazolam resulted in similar 
proportions of time within the target range of 
−2 to +1 on the Richmond Agitation–Sedation 
Scale among patients, but those assigned to re-
ceive dexmedetomidine had a reduced risk of 
delirium and spent less time undergoing me-
chanical ventilation.21 As compared with a loraz-
epam infusion, sedation with dexmedetomidine 
Table 3. Scoring Systems for the Diagnosis of Delirium  
in Critically Ill Patients.*
System, Scoring Method, and Criteria
Confusion Assessment Method for the ICU (CAM-ICU)†
Scoring is positive or negative according to the presence 
or absence of criteria listed
Patient must be sufficiently awake (RASS score, −3 or more) 
for assessment according to the following criteria:
An acute change from mental status at base line or 
fluctuating mental status during the past 24 hr 
(must be true to be positive)
More than 2 errors on a 10­point test of atten tion to 
voice or pictures (must be true to be positive)
If the RASS is not 0 and the above two criteria are 
positive, the patient is delirious
If the RASS is 0 and the above two criteria are posi­
tive, test for disorganized thinking using 4 yes/no 
questions and a 2­step command; >1 error means 
the patient is delirious; ≤1 error excludes delirium
Intensive Care Delirium Screening Checklist (ICDSC)‡
A score of ≥4 is positive for delirium (with scores of 1 to  
3 termed “subsyn dromal delirium”)
Patient must show at least a response to mild or moderate 
stimulation. Then score 1 point for each of the 
following features, as assessed in the manner 
thought appropriate by the clinician:
Anything other than “normal wakefulness”
Inattention
Disorientation
Hallucination
Psychomotor agitation
Inappropriate speech or mood
Disturbance in sleep or wake cycle
Fluctuation in symptoms
* RASS denotes Richmond Agitation–Sedation Scale.
† Data are from Ely et al.41
‡ Data are from Bergeron et al.29
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resulted in more time at the target level of seda-
tion and longer survival without delirium or 
coma.20 In a multicenter European trial, patients 
were randomly assigned to continue treatment 
with their current sedative (midazolam or pro-
pofol) or to switch to sedation with up to 1.4 μg 
of dexmedetomidine per kilogram of body weight 
per hour.19 There were no between-group differ-
ences in the proportion of time at the target 
level of sedation. The rates of the composite end 
point of agitation, anxiety, or delirium were 
lower with dexmedetomidine than with propo-
fol, but the rates with dexmedetomidine were 
equivalent to those with midazolam. When de-
lirium was assessed with the use of the CAM-
ICU 48 hours after sedation was discontinued, 
there were no significant differences among the 
groups.
Specific indication for sedation
Pain controlled
Pain controlled
Status epilepticus
Intracranial hypertension
Severe respiratory failure with or 
without neuromuscular blockade
Assess for delirium
Mainly hypoactive
delirium
Mainly hyperactive 
delirium
Treat with antidelirium 
medication (or 
nonpharmacologic 
measures)
Treat with nonpharmacologic
measures (e.g., physical therapy, 
earplugs or quiet room, 
cognitive stimulation,
repeated reorientation) 
No
delirium
Delirium controlled
Assess pain and treat with opioid 
or other drug or technique
Assess pain and treat with opioid 
or other drug or technique
Assess need for sedative medication to achieve target RASS score of –2 to 0 
(lightly sedated but responsive at least to voice)
Reassess analgesic, antidelirium, and sedative requirement regularly
(e.g., every 4 hr or with observed change)
Target sedation to indication:
• Seizure control
• Acceptable intracranial 
   pressure
• Tolerance of hypercarbia 
   or necessary ventilator 
   settings
• No awareness when being 
   treated with neuromuscular 
   blocking agent
Regularly assess the need 
for this level of sedation
The target sedation level is
likely to be best communicated
using the RASS scale
Target sedation to 
RASS score of –2 to 0
Do not use sedative 
medication
Yes
Yes
Yes
Yes
No
No
No
No
Yes
Figure 2. Algorithm for the Coordinated Management of Pain, Agitation, and Delirium.
The application of this algorithm — which combines the use of analgesics, antidelirium agents, sedatives, and non­
pharmacologic techniques — will depend on the individual situation for each patient. For example, patients under­
going surgery who are suitable candidates for rapid extubation and who have little risk of delirium may be treated 
only with analgesia and rapidly diminishing sedation. RASS denotes Richmond Agitation–Sedation Scale, which 
ranges from −5 to +4, with more negative scores indicating deeper sedation and more positive scores indicating in­
creasing agitation, and with 0 representing the appearance of calm and normal alertness.
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Treatment
There is very little evidence to guide the manage-
ment of established delirium, and most existing 
trials were categorized by the investigators as pi-
lot studies. Only one small placebo-controlled 
trial supports the efficacy of a drug treatment for 
established delirium in patients in the ICU. In a 
study of 36 patients who were randomly assigned 
to treatment with quetiapine or placebo, delirium 
resolved faster in patients who received quetia-
pine. The use of quetiapine also increased the 
number of patients who were discharged to their 
own home or to rehabilitation.52 A study of 103 
patients who were randomly assigned to receive 
regular haloperidol, ziprasidone, or placebo 
showed no significant differences in the number 
of days that patients survived without delirium or 
coma.53 The single study comparing haloperidol 
with an atypical antipsychotic (olanzapine) 
showed equivalent efficacy.54 None of these trials 
distinguished between hyperactive and hypoac-
tive delirium.
In a pilot study comparing dexmedetomidine 
with haloperidol in patients with hyperactive de-
lirium, dexmedetomidine was associated with a 
shorter time to extubation and shorter length of 
stay in the ICU.55 This finding is supported by a 
randomized trial of dexmedetomidine versus 
midazolam in which patients with delirium at 
the time of enrollment had a more rapid resolu-
tion of delirium if they were assigned to receive 
dexmedetomidine than if they were assigned to 
receive midazolam.21 However, definitive evidence 
supporting the use of dexmedetomidine for the 
treatment of delirium is not currently available.
Qua li t y Improv emen t 
Techniques
Frameworks that facilitate the aforementioned 
approaches have been developed. These include 
the “pain, agitation, and delirium” (PAD) guide-
lines44 and the “spontaneous awakening and 
breathing coordination, attention to the choice 
of sedation, delirium monitoring, and early mo-
bility and exercise” (ABCDE) bundle.56 These 
guidelines emphasize improving team commu-
nication in the ICU, standardizing care process-
es, and prioritizing methods to lighten sedation 
and facilitate early mobilization and extubation. 
Each guideline recognizes the conceptual evolu-
tion from spontaneous-breathing trials and in-
terruption of sedation to a comprehensive ap-
proach to monitoring and managing pain, 
agitation, and delirium.
Conclusions
Accumulating evidence suggests that the man-
agement of sedation and delirium can have an 
important effect on the outcomes of patients 
who are treated in ICUs. Currently available data 
suggest that the best outcomes are achieved with 
the use of a protocol in which the depth of seda-
tion and the presence of pain and delirium are 
routinely monitored, pain is treated promptly 
and effectively, the administration of sedatives is 
kept to the minimum necessary for the comfort 
and safety of the patient, and early mobilization 
is achieved whenever possible (Fig. 2).
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